Article Versions Notes

Giannini EG, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F, Morisco F, et al. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers. 2019; 11(11):1689. https://doi.org/10.3390/cancers11111689

Giannini, Edoardo G., Andrea Aglitti, Mauro Borzio, Martina Gambato, Maria Guarino, Massimo Iavarone, Quirino Lai, Giovanni Battista Levi Sandri, Fabio Melandro, Filomena Morisco, and et al. 2019. "Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice" Cancers 11, no. 11: 1689. https://doi.org/10.3390/cancers11111689

Giannini, E. G., Aglitti, A., Borzio, M., Gambato, M., Guarino, M., Iavarone, M., Lai, Q., Levi Sandri, G. B., Melandro, F., Morisco, F., Ponziani, F. R., Rendina, M., Russo, F. P., Sacco, R., Viganò, M., Vitale, A., Trevisani, F., & on behalf of the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. (2019). Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 11(11), 1689. https://doi.org/10.3390/cancers11111689